Evidence map›Paper›PMID 26062903›Full record

ArticleBMC infectious diseases2015

Antibiotic use for Vibrio infections: important insights from surveillance data.

Kam Cheong Wong, Anthony M Brown, Georgina M Luscombe, Shin Jie Wong, Kumara Mendis

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 86 citations in OpenAlex.

  1. Article
  2. New microbes and new infections · 2026
    Article
  3. Article
  4. Septic shock caused by non-O1/non-O139World journal of emergency medicine · 2025
    Article
  5. Review
  6. Antimicrobial resistance ofApplied and environmental microbiology · 2025
    Article
  7. Article
  8. Clinical case reports · 2025
    Article
  9. Article
  10. Public health aspects ofEFSA journal. European Food Safety Authority · 2024
    Article
  11. Antibiotic resistance trends amongApplied and environmental microbiology · 2024
    Article
  12. Characterization of aFood science and biotechnology · 2024
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Kam Cheong WongBathurst Rural Clinical School, School of Medicine, University of Western Sydney, PO Box 9008, Bathurst, NSW, 2795, Australia. k.wong@uws.edu.au.
Anthony M BrownSchool of Rural Health, Sydney Medical School, University of Sydney, PO Box 1191, Orange, 2800, NSW, Australia. tony.brown@sydney.edu.au.
Georgina M LuscombeSchool of Rural Health, Sydney Medical School, University of Sydney, PO Box 1191, Orange, 2800, NSW, Australia. georgina.luscombe@sydney.edu.au.
Shin Jie WongBathurst Rural Clinical School, School of Medicine, University of Western Sydney, PO Box 9008, Bathurst, NSW, 2795, Australia. shin_jie91@hotmail.com.
Kumara MendisBathurst Rural Clinical School, School of Medicine, University of Western Sydney, PO Box 9008, Bathurst, NSW, 2795, Australia. k.mendis@uws.edu.au.
The University of Sydney · AUShinshu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is a paucity of data on the in vivo efficacy of antibiotics for lethal Vibrio species. Analyses of long-term surveillance datasets may provide insights into use of antibiotics to decrease mortality.

methodsThe United States Centers for Disease Control and Prevention (CDC) Cholera and Other Vibrio Illness Surveillance (COVIS) dataset from 1990 to 2010, with 8056 records, was analysed to ascertain trends in antibiotics use and mortality.

resultsTwo-thirds of patients (5243) were prescribed antibiotics - quinolones (56.1 %), cephalosporins (24.1 %), tetracyclines (23.5 %), and penicillins (15.4 %). Considering all Vibrio species, the only class of antibiotic associated with reduced odds of mortality was quinolone (odds ratio 0.56, 95 % CI 0.46-0.67). Patients with V. vulnificus treated according to CDC recommendations had lower mortality (quinolone alone: 16.7 %, 95 % CI 10.2-26.1; tetracycline plus cephalosporin: 21.7 %, 16.8-27.5; no antibiotic: 51.1 %, 45.6-56.7; each p < 0.001). Cephalosporin alone was associated with higher mortality (36.8 %, 28.2-46.3). For V. cholerae non-O1, non-O139, mortality rates were lower for quinolone (0 %, 0-2.0) or tetracycline (4.3 %, 1.2-14.5) compared to no antibiotic (9.3 %, 6.4-13.3). For all Vibrio species, mortality rates increased with number of antibiotics in the treatment regimen (p < 0.001). Treatment regimens that included quinolone were associated with lower mortality rates regardless of the number of antibiotics used. The main clinical syndromes of patients with V. vulnificus infection were septicaemia (53.1 %) and wound infections (30.6 %). Mortality among V. vulnificus patients with septicaemia was significantly higher than for other clinical syndromes (p < 0.001). In a multivariate regression model, mortality in cases with V. vulnificus was associated with presence of pre-existing conditions (ORs ranged from 4.52 to 10.30), septicaemia (OR 2.64, 95 % CI 1.92-3.63) and no antibiotic treatment (OR 7.89, 95 % CI 3.94-15.80).

conclusionIn view of the lack of randomized control trials, surveillance data may inform treatment decisions for potentially lethal Vibriosis. Considering all Vibrio species, use of quinolones is associated with lower mortality and penicillin alone is not particularly effective. For the most lethal species, V. vulnificus, treatment that includes either quinolone or tetracycline is associated with lower mortality than cephalosporin alone. We recommend treating patients who present with a clinical syndrome suggestive of V. vulnificus infection with a treatment regimen that includes a quinolone.

Indexed as

AdultAnti-Bacterial AgentsCephalosporinsFemaleHumansMaleMiddle AgedOdds RatioPenicillinsQuinolonesSurvival AnalysisTetracyclineUnited StatesVibrioVibrio InfectionsAnti-Bacterial AgentsCephalosporinsPenicillinsQuinolonesTetracycline

Identifiers

PMID26062903
PMCPMC4464855
OpenAlexW1604087868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.